Synergistic antitumor and immunomodulatory effects of

Liuqing Yang, Zelong Li, Yalin Li, Qi Zhang, Heping Zhang

Abstract read

In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

The effects of probiotics duration and type on immunotherapy efficacy in non-small cell lung cancer with or without antibiotics.Journal of translational medicine · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Liuqing YangKey Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, Inner Mongolia, China.

Zelong LiKey Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, Inner Mongolia, China.

Yalin LiKey Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, Inner Mongolia, China.

Qi ZhangDepartment of Colorectal Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.

Heping ZhangKey Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, Inner Mongolia, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 have revolutionized cancer immunotherapy but remain limited by low response rates, immune-related adverse events (irAEs), and reduced efficacy following antibiotic exposure. The gut microbiota critically influences ICI responsiveness, and Methods: We systematically characterized Results: Conclusions:

Indexed as

Bifidobacterium animalisImmune Checkpoint InhibitorsNeoplasmsProbioticsProgrammed Cell Death 1 ReceptorAnimalsCell Line, TumorCytokinesFemaleGastrointestinal MicrobiomeHumansImmunomodulationMiceTumor MicroenvironmentCytokinesImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptorantineoplasticanti–PD-1 therapyBifidobacterium animalis subsp. lactis V9gut microbiotaimmune modulation

Identifiers

PMID42273689

DOI10.3389/fimmu.2026.1791276

PMCPMC13246658

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.